Old Web
English
Sign In
Acemap
>
authorDetail
>
Mark Kozloff
Mark Kozloff
University of Chicago
Medicine
Immunology
Axitinib
Paclitaxel
Adverse effect
4
Papers
54
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440)
2018
Blood
Stephan Stilgenbauer
Franck Morschhauser
Clemens-Martin Wendtner
Guillaume Cartron
Michael Hallek
Barbara Eichhorst
Mark Kozloff
Thomas A. Giever
Gerard Lozanski
Yanwen Jiang
Huang Huang
Daniela Soriano Pignataro
William Schary
Kathryn Humphrey
Mehrdad Mobasher
Gilles Salles
Show All
Source
Cite
Save
Citations (1)
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.
2012
British Journal of Cancer
L P Martin
Mark Kozloff
R. S. Herbst
Thomas A. Samuel
Sinil Kim
Brad Rosbrook
Michael A. Tortorici
Ying Chen
Jamal Tarazi
A.J. Olszanski
T. A. Rado
A Starr
Roger B. Cohen
Show All
Source
Cite
Save
Citations (21)
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
2012
British Journal of Cancer
Mark Kozloff
L P Martin
M. Krzakowski
Thomas A. Samuel
T. A. Rado
E. Arriola
J de Castro Carpeño
Roy S. Herbst
Jamal Tarazi
Sinil Kim
Brad Rosbrook
Michael A. Tortorici
A.J. Olszanski
Roger B. Cohen
Show All
Source
Cite
Save
Citations (23)
Phase Ib study of drozitumab combined with first-line FOLFOX plus bevacizumab (BV) in patients (pts) with metastatic colorectal cancer (mCRC).
2011
Journal of Clinical Oncology
Mark Kozloff
Wells A. Messersmith
Amy V. Kapp
Avi Ashkenazi
Stephanie Royer-Joo
Chia C. Portera
Zev A. Wainberg
Show All
Source
Cite
Save
Citations (9)
1